Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas

被引:30
作者
Au, WY [1 ]
Horsman, DE [1 ]
Ohno, H [1 ]
Klasa, RJ [1 ]
Gascoyne, RD [1 ]
机构
[1] Dept Pathol & Lab Med, Vancouver, BC, Canada
关键词
t(14; 19); BCL3; atypical CLL; secondary events;
D O I
10.1080/10428190290016935
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The recurrent cytogenctic (CG) abnormality t(14;19)(q32;q13) involving the oncogene BCL3 is described in patients with atypical chronic lymphocytic leukemia (CLL). We report four patients with non-Hodgkin's lymphoma (NHL) bearing t(l 4; 19). All cases were female and their age ranged from 62 to 91. Histologically, there were two cases of small lymphocytic lymphoma (SLL), both CD11c positive with atypical morphology, one case of Burkitt like lymphoma (BLL), and one case of diffuse large cell lymphoma (DLC-L). One SLL patient showed t(14;19) as the sole abnormality and experienced a benign course for 8 years. The other three cases showed secondary CG progression, including tetraploidy, del(6q), t(8;22) and del(13q). These cases were aggressive in clinical behavior, including an SLL case which transformed to DLC lymphoma in 4 months. Southern analysis and long distance PCR confirmed BCL3/IgH Calpha translocation in one case. We propose that NHLs with t(14;19) may have evolved from the same spectrum of disease as atypical CLL. The poor prognosis of t(14;19) disease is associated with the occurrence of recurrent secondary CG changes, commonly found in B cell lymphoproliferative diseases.
引用
收藏
页码:813 / 816
页数:4
相关论文
共 22 条
  • [1] Akasaka T, 1996, BLOOD, V88, P985
  • [2] Au WY, 2000, HAEMATOLOGICA, V85, P1225
  • [3] BLOOMFIELD CD, 1983, CANCER RES, V43, P2975
  • [4] TRANSLOCATION (14-19) IN ACUTE BIPHENOTYPIC LEUKEMIA
    CARTER, R
    DUBE, I
    MCKEITHAN, T
    CARSTAIRS, K
    DEHARVEN, E
    BAILEY, D
    SCOTT, JG
    [J]. CANCER GENETICS AND CYTOGENETICS, 1991, 53 (01) : 67 - 73
  • [5] The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators
    Dechend, R
    Hirano, F
    Lehmann, K
    Heissmeyer, V
    Ansieau, S
    Wulczyn, FG
    Scheidereit, C
    Leutz, A
    [J]. ONCOGENE, 1999, 18 (22) : 3316 - 3323
  • [6] Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner, H
    Stilgenbauer, S
    Benner, A
    Leupolt, E
    Kröber, A
    Bullinger, L
    Döhner, K
    Bentz, M
    Lichter, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) : 1910 - 1916
  • [7] B lymphocytes differentially use the Rel and nuclear factor κB1 (NF-κB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells
    Grumont, RJ
    Rourke, IJ
    O'Reilly, LA
    Strasser, A
    Miyake, K
    Sha, W
    Gerondakis, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (05) : 663 - 674
  • [8] PROGNOSTIC SUBGROUPS IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA DEFINED BY SPECIFIC CHROMOSOMAL-ABNORMALITIES
    JULIUSSON, G
    OSCIER, DG
    FITCHETT, M
    ROSS, FM
    STOCKDILL, G
    MACKIE, MJ
    PARKER, AC
    CASTOLDI, GL
    CUNEO, A
    KNUUTILA, S
    ELONEN, E
    GAHRTON, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (11) : 720 - 724
  • [9] Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: Cytogenetics predict outcome and reflect clinical presentation
    Macpherson, N
    Lesack, D
    Klasa, R
    Horsman, D
    Connors, JM
    Barnett, M
    Gascoyne, RD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1558 - 1567
  • [10] McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.3.CO